Chemomab Therapeutics’ (CMMB) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Chemomab Therapeutics (NASDAQ:CMMB) in a research report sent to investors on Friday,Benzinga reports. Oppenheimer currently has a $11.00 price objective on the stock, down from their previous price objective of $13.00.

Chemomab Therapeutics Stock Down 3.7 %

Shares of CMMB opened at $1.68 on Friday. Chemomab Therapeutics has a 12-month low of $0.42 and a 12-month high of $2.55. The firm has a market capitalization of $24.05 million, a price-to-earnings ratio of -1.68 and a beta of 0.53. The stock’s 50-day moving average price is $1.56 and its 200 day moving average price is $1.28.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period in the prior year, the business earned ($0.72) EPS. Equities research analysts expect that Chemomab Therapeutics will post -0.9 EPS for the current year.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Sphera Funds Management LTD. acquired a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent quarter. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).